Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease

To determine the biologic variability of N-terminal pro-brain natriuretic peptide (NTproBNP) in healthy dogs and dogs with various stages of myxomatous mitral valve disease (MMVD). Thirty-eight privately owned dogs: 28 with MMVD and 10 healthy controls. Prospective clinical study with comprehensive...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary cardiology 2017-04, Vol.19 (2), p.124-131
Main Authors: Winter, Randolph L., Saunders, Ashley B., Gordon, Sonya G., Buch, Jesse S., Miller, Matthew W.
Format: Article
Language:English
Subjects:
Animals
Biomarkers - blood
Canine
Cardiac biomarker
Case-Control Studies
Dog Diseases - blood
Dogs - blood
Female
Male
Mitral regurgitation
Mitral Valve Insufficiency - blood
Mitral Valve Insufficiency - veterinary
Natriuretic Peptide, Brain - blood
Peptide Fragments - blood
Prospective
Prospective Studies
Reference Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the biologic variability of N-terminal pro-brain natriuretic peptide (NTproBNP) in healthy dogs and dogs with various stages of myxomatous mitral valve disease (MMVD). Thirty-eight privately owned dogs: 28 with MMVD and 10 healthy controls. Prospective clinical study with comprehensive evaluation used to group dogs as healthy or into three stages of MMVD based on current guidelines. NTproBNP was measured hourly, daily, and weekly. For each group, analytical (CVA), within-subject (CVI), and between-subject (CVG) coefficients of variability were calculated in addition to percent critical change value (CCV) and index of individuality (IoI). For healthy dogs, calculated NTproBNP values were: CVA = 4.2%; CVI = 25.2%; CVG = 49.3%; IoI = 0.52, and CCV = 70.8%. For dogs with MMVD, calculated NTproBNP values were: CVA = 6.2%; CVI = 20.0%; CVG = 61.3%; IoI = 0.34, and CCV = 58.2%. Biologic variability affects NTproBNP concentrations in healthy dogs and dogs with MMVD. Monitoring serial individual changes in NTproBNP may be clinically relevant in addition to using population-based reference ranges to determine changes in disease status.
ISSN:1760-2734
1875-0834
DOI:10.1016/j.jvc.2016.11.001